绘制大脑在骨关节炎中的作用:预防的新证据
Jingkai Di1,2, Yujia Xi3, Yaru Liu4
1Department of Orthopedics, Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Journal of multidisciplinary healthcare
|June 30, 2025
概括
这项研究揭示了与骨关节炎 (OA) 风险相关的大脑结构特征. 特定的脑成像衍生的表型 (IDP) 为OA预防策略提供了潜在的目标.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 整形外科 整形外科 整形外科
背景情况:
- 骨关节炎 (OA) 是一种具有复杂病因的退行性关节疾病.
- 了解中枢神经系统结构与OA之间的关系,对于开发新的预防策略至关重要.
研究的目的:
- 调查大脑结构参数与患骨关节炎 (OA) 的风险之间的因果关系.
- 为了确定潜在的基于大脑的生物标志物用于OA预防.
主要方法:
- 使用了双样本的门德尔随机化方法.
- 采用了来自英国生物库的3913个脑成像衍生的表型 (IDP) 作为暴露数据.
- 使用大规模的欧洲OA数据进行结果分析,并进行敏感性和异质性分析以确保稳定性.
主要成果:
- 确定了13个与OA风险显著相关的大脑区域.
- 在带状海马回形中增加的分数异构性 (FA) 和中增加的方向扩散 (OD) 发现了保护作用.
- 观察到OA风险增加,与中部乳头管中的OD增加和大脑脚中的细胞内体积分数 (ICVF) 增加有关.
结论:
- 建立了特定的大脑结构参数和OA风险之间的遗传联系,支持骨脑轴概念.
- 建议潜在的临床策略,包括针对神经通路的综合性疼痛-精神运动干预措施,以预防OA.
相关概念视频
Osteoclasts in Bone Remodeling
3.2K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.2K
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


